scispace - formally typeset
D

David M. O'Malley

Researcher at Ohio State University

Publications -  359
Citations -  12931

David M. O'Malley is an academic researcher from Ohio State University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 43, co-authored 270 publications receiving 8694 citations. Previous affiliations of David M. O'Malley include The Ohio State University Wexner Medical Center.

Papers
More filters
Journal ArticleDOI

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

Eric Pujade-Lauraine, +110 more
- 01 Sep 2017 - 
TL;DR: Olaparib tablet maintenance treatment provided a significant progression-free survival improvement with no detrimental effect on quality of life in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation.
Journal ArticleDOI

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, +116 more
- 28 Oct 2017 - 
TL;DR: This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Journal ArticleDOI

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

Catherine M. Phelan, +443 more
- 01 May 2017 - 
TL;DR: Integrated analyses of genes and regulatory biofeatures at each locus predicted candidate susceptibility genes, including OBFC1, a new candidate susceptibility gene for low-grade and borderline serous EOC.